Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018
MC Sorbo, V Cento, VC Di Maio, AYM Howe… - Drug Resistance …, 2018 - Elsevier
Nowadays, due to the development of potent Direct-Acting Antiviral Agents (DAAs) that
specifically target NS3, NS5A and NS5B viral proteins, several new and highly efficacious …
specifically target NS3, NS5A and NS5B viral proteins, several new and highly efficacious …
Current status and future development of infectious cell-culture models for the major genotypes of hepatitis C virus: essential tools in testing of antivirals and emerging …
In this review, we summarize the relevant scientific advances that led to the development of
infectious cell culture systems for hepatitis C virus (HCV) with the corresponding challenges …
infectious cell culture systems for hepatitis C virus (HCV) with the corresponding challenges …
[HTML][HTML] Theaflavins, polyphenols of black tea, inhibit entry of hepatitis C virus in cell culture
P Chowdhury, ME Sahuc, Y Rouillé, C Rivière… - PLoS …, 2018 - journals.plos.org
The treatment of hepatitis C virus (HCV) infection by combination of direct acting antivirals
(DAA), with different mode of action, has made substantial progress in the past few years …
(DAA), with different mode of action, has made substantial progress in the past few years …
Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: the SIMPLIFY study
Background This study investigated treatment adherence among people with recent
injecting drug use in a study of sofosbuvir/velpatasvir therapy for HCV infection. Methods …
injecting drug use in a study of sofosbuvir/velpatasvir therapy for HCV infection. Methods …
Direct‐acting antiviral treatment of chronic HCV‐infected patients on opioid substitution therapy: Still a concern in clinical practice?
S Christensen, P Buggisch, S Mauss, KHW Böker… - …, 2018 - Wiley Online Library
Background and aims There is limited real‐world information on the effectiveness of antiviral
treatment of chronic hepatitis C virus (HCV) infection with direct‐acting antivirals (DAA) in …
treatment of chronic hepatitis C virus (HCV) infection with direct‐acting antivirals (DAA) in …
Molecular design, synthesis and biological evaluation of cage compound-based inhibitors of hepatitis C virus p7 ion channels
VA Shiryaev, EV Radchenko, VA Palyulin… - European Journal of …, 2018 - Elsevier
The hepatitis C caused by the hepatitis C virus (HCV) is an acute and/or chronic liver
disease ranging in severity from a mild brief ailment to a serious lifelong illness that affects …
disease ranging in severity from a mild brief ailment to a serious lifelong illness that affects …
Host-targeting therapies for hepatitis C virus infection: current developments and future applications
E Crouchet, F Wrensch, C Schuster… - Therapeutic …, 2018 - journals.sagepub.com
Chronic hepatitis C virus (HCV) infection is a leading cause of chronic liver diseases and
hepatocellular carcinoma (HCC) worldwide. In the past few years, anti-HCV therapies have …
hepatocellular carcinoma (HCC) worldwide. In the past few years, anti-HCV therapies have …
Ultrasensitive spectrofluorimetric method for rapid determination of daclatasvir and ledipasvir in human plasma and pharmaceutical formulations
Direct-acting antivirals (DAAs) represent a revolution in the treatment of chronic hepatitis C
which have emerged at an extremely rapid pace over the past few years. DAAs act directly …
which have emerged at an extremely rapid pace over the past few years. DAAs act directly …
Potent inhibitors of hepatitis C virus NS3 protease: employment of a difluoromethyl group as a hydrogen-bond donor
B Zheng, SV D'Andrea, LQ Sun, AX Wang… - ACS Medicinal …, 2018 - ACS Publications
The design and synthesis of potent, tripeptidic acylsulfonamide inhibitors of HCV NS3
protease that contain a difluoromethyl cyclopropyl amino acid at P1 are described. A …
protease that contain a difluoromethyl cyclopropyl amino acid at P1 are described. A …
Nano-magnetite/ionic liquid crystal modifiers of carbon nanotubes composite electrode for ultrasensitive determination of a new anti-hepatitis C drug in human serum
NF Atta, YM Ahmed, A Galal - Journal of Electroanalytical Chemistry, 2018 - Elsevier
Direct-acting antivirals (DAAs) are promising redeemer for patients suffering from Hepatitis C
virus (HCV). From the clinical point of view, it is crucial to determine the level of a newly …
virus (HCV). From the clinical point of view, it is crucial to determine the level of a newly …